Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days
NºPublicación: EP3145547A1 29/03/2017
IFOM FOND ST FIRC DI ONCOLOGIA MOLECOLARE [IT]
UNIVERSITA' DEGLI STUDI DI MILANO [IT]
An inhibitor of Wnt/β-catenin signaling for use in the treatment and/or prevention of a pathology characterized by vascular malformation. The inhibitor may be a small molecule, a protein, a peptide or an antisense nucleic acid. The invention also relates to pharmaceutical compositions and to method of treatment.
NºPublicación: EP3145508A1 29/03/2017
THE MEDICINES CO [US]
Provided is a pharmaceutical composition comprising clevidipine in a sterile, ready to use, physically stable, aqueous dispersion of nanoparticles that stabilizes clevidipine against formation of impurities and is suitable for parenteral administration.
NºPublicación: WO2017045192A1 23/03/2017
TIANJIN MEDICAL UNIV [CN]
A tumor-targeting nanomicelle capable of loading a drug by using acousto-optical power, a preparation method therefor, and applications thereof. The drug loading nanomicelle is structurally a nanocomposite formed by porphyrin compounds and anthracycline chemotherapy drugs by means of π-π conjugate actions, and a hydrophilic housing is formed by wrapping the nanocomposite by using an amphiphilic block copolymer having a polyethylene oxide (PEO) polyethyleneglycol (PEG) hydrophilic blocks.
NºPublicación: US2017080026A1 23/03/2017
TOVARISTVO Z OBMEZHENOU VIDPOVIDALNISTU NANOMEDTRAST [UA]
A medicinal product opening voltage-gated ion channels in mammalian vascular smooth muscle cells comprises the colloidal solution of gold nanoparticles at a concentration required for remote opening of voltage-gated ion channels in mammalian vascular smooth muscle cells.
NºPublicación: US2017080099A1 23/03/2017
CALIFORNIA INST OF TECHN [US]
Carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid and a linkage cleavable under reducing conditions, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle and related compositions, methods and systems.
NºPublicación: US2017080098A1 23/03/2017
UNIV NORTH CAROLINA STATE [US]
A graft copolymer having drug-containing side chains is described. The graft copolymer can be prepared, for example, by directly polymerizing a drug-containing monomer on multiple sites of a linear copolymer. When exposed to water, the graft copolymer can form uniform nanocarriers, e.g., nanomicelles, optionally encapsulating additional drugs, e.g., non-covalently in the interior of the nanocarriers, for coordinated drug delivery of a plurality of drugs. Also described herein is the use of the nanocarriers for delivery of therapeutic agents, particularly the dual delivery of chemotherapeutic agents to treat tumors.
NºPublicación: US2017080114A1 23/03/2017
IMGT CO LTD [KR]
The present invention provides a dual-purpose photoacoustic tomography (PAT)/ultrasound contrast agent comprising: (a) a micro-bubble containing gas and porphyrin therein; and (b) nanoparticles bound on a surface of the micro-bubble and containing a drug. The contrast agent of the present invention can be used in both the ultrasound diagnosis and the photoacoustic image diagnosis, and can significantly increase the accuracy of photoacoustic images.
NºPublicación: US2017080112A1 23/03/2017
UNIV DE NANTES [FR]
CENTRE NAT DE LA RECH SCIENT (CNRS) [FR]
Disclosed are magnetic and fluorescent nanoassemblies having reverse architectures. Especially, the nanoassemblies include an organic fluorescent inner core and magnetic nanoparticles contacting the surface of the fluorescent core. The nanoassemblies may further be coated by a polymer adsorbed at its surface, the polymer being optionally functionalized. Also described is a process for manufacturing the nanoassemblies, as well as use of the nanoassemblies, especially for multimodal imaging; in vitro and/or in vivo diagnostics through multimodal imaging; ex vivo sensing and/or extraction; and/or therapy.
NºPublicación: US2017080078A1 23/03/2017
OHIO STATE INNOVATION FOUNDATION [US]
Disclosed herein are methods and compositions for treating or preventing Porcine reproductive and respiratory syndrome (PRRS) infection in a subject.
NºPublicación: US2017080084A1 23/03/2017
GLAXOSMITHKLINE BIOLOGICALS SA [BE]
Oil-in-water emulsions with small droplet sizes can be formed without requiring either microfluidisation or heating to cause phase inversion, but rather by simple mixing of a pre-mixed composition of oil and a surfactant component comprising at least one surfactant component with aqueous material. The HLB value of the surfactant component can be selected to give a composition which, on mixing with a volume excess of aqueous material, spontaneously forms an oil in water emulsion with submicron oil droplets having a diameter <250 nm, suitable for filter sterilisation. Droplet diameters of <40 nm can also be achieved.
NºPublicación: US2017079895A1 23/03/2017
ANTERIOS INC [US]
The present invention provides nanoparticle compositions including one or more peptides. The present invention achieves transdermal delivery of such peptides without the need for peptide modification, or for use of chemical or mechanical abrasion or disruption of skin.
NºPublicación: US2017079918A1 23/03/2017
CRISTAL DELIVERY B V [NL]
The present invention is directed to vaccination composition comprising a particle comprising a polymer matrix incorporating an adjuvant and/or an antigen, to method of making them and use. Particularly, the present invention results in adjuvants and/or antigens, covalently entrapped in or coupled to polymer carriers or polymeric devices, such as micelles, nanoparticles, microspheres and other types of polymer devices for controlled release; the adjuvant and/or antigen are covalently bonded in or to the polymer carriers or polymeric devices.
NºPublicación: US2017079930A1 23/03/2017
AGE NANOTECH LTD [GB]
AGA NANOTECH LTD [GB]
A nano- or micro-scale therapeutic agent is provided for use in the treatment of an infection of a human or animal. The agent includes micro- and/or nano-particle carriers loaded with at least one inert precursor chemical. The carriers encapsulate the precursor which after release from the carrier are activatable by the physiological milieu in situ at the site of the infection to form an antimicrobial agent. Preferably, the precursor chemical or chemicals form an oxidative biocide on release, which oxidative biocide is hydrogen peroxide. Advantageously, the precursor chemicals also include an acetyl donor that on release reacts with the hydrogen peroxide to produce a mixture of peracetic acid and hydrogen peroxide. The carrier is preferably in the form of micro- and/or nano-particles that have been manufactured using a thermally induced phase separation (TIPS) process, for example the carrier may be a biodegradable polymer such as poly(lactic-co-glycolic acid) (PLGA).
NºPublicación: US2017079909A1 23/03/2017
UNIV CALIFORNIA [US]
The present invention provides for compositions comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle. The present invention also provides for the use of the above compositions for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject. The exemplary toxin is a biological toxin such as a viral, bacterial, fungal, plant or animal toxin.
NºPublicación: WO2017048944A1 23/03/2017
BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM [US]
Methods for sensitizing target cells to ionizing radiation are provided comprising the administration of high-Z particles (e.g., gold nanoparticles) in conjunction with a de-aggregation agent. In some aspects, particles comprise a targeting molecule to enable cellular uptake by the target cells. Pharmaceutical compositions comprising high-Z particles and de-aggregation agents are also provided.
NºPublicación: WO2017049083A2 23/03/2017
DFB SORIA LLC [US]
Disclosed are compositions and methods useful for enhancing the skin penetration of drug nanoparticles. The compositions can be hydrophobic and include a hydrophobic carrier, a volatile silicone fluid, and drug nanoparticles. Also disclosed are methods for inhibiting crystal growth of drug nanoparticles in an aqueous carrier or a hydrophobic carrier. Further, methods to topically treat psoriasis using compositions containing nanoparticles of paclitaxel or other taxanes are disclosed.
NºPublicación: WO2017046037A1 23/03/2017
The present invention concerns nanoparticles of one or more active ingredient, such as doxorubicin with controlled average diameter, their process of preparation, their formulations and their therapeutic uses.
NºPublicación: WO2017048789A1 23/03/2017
THE BOARD OF REGENTS OF THE UNIV OF TEXAS SYSTEM [US]
Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.
NºPublicación: WO2017048807A1 23/03/2017
JRX BIOTECHNOLOGY INC [US]
The present disclosure generally relates to approaches for improving water absorption and retention by the skin's surface. In particular, the disclosure provides compositions and methods for preparing mixtures comprised of ethoxylated oils and water or mixtures comprised of micro or nano emulsions and water, which provide enhanced skin hydration or moisturization to a subject.
NºPublicación: WO2017049265A1 23/03/2017
HANN LENN [US]
A medical apparatus, such as a cannula tip for a peripheral vein of a human body, wherein the medical apparatus includes a micro- or nano-structured superhydrophilic basecoat and a liquid topcoat, together comprising a superhydrophobic coating, which inhibit occlusion and/or catheter related bloodstream infection. The topcoat can further include compatible drugs and/or biomaterials to enhance compatibility and/or enhance durability of the topcoat.
NºPublicación: WO2017049125A1 23/03/2017
LA JOLLA NANOMEDICAL [US]
Embodiments of nanoparticle systems and methods of producing nanoparticle systems configured to target particular cellular activity in an animal or human including a signaling pathway expression of mammal cellular activity and treat cells producing the targeted cellular activity by exposing the nanoparticle system to electromagnetic radiation in a predetermined range of wavelengths. Other embodiments may be described and claimed.
NºPublicación: WO2017047364A1 23/03/2017
SHIMADZU CORP [JP]
Each nanoparticle according to the present invention is composed of a molecular assembly that contains an amphiphilic block polymer having a hydrophilic block and a hydrophobic block. It is preferable that the amphiphilic block polymer has biodegradability. Nanoparticles according to the present invention are obtained by granulating an amphiphilic block polymer in the presence of an amino acid having an isoelectric point of 7 or less. In one embodiment of the present invention, granulation is carried out by bringing a solution containing the amphiphilic block polymer or a dried product of the solution into contact with an aqueous liquid. By having the amino acid having an isoelectric point of 7 or less contained in at least one of the solution containing the amphiphilic block polymer or the aqueous liquid, granulation is able to be carried out in the presence of the amino acid.
NºPublicación: WO2017045628A1 23/03/2017
ALAYA (SHANGHAI\uFF09BIOSCIENCE CO LTD [CN]
Non-vesicular nanoparticles which have antibacterial activity and are made from a C8-C28 fatty acid or a derivative thereof, a surfactant and an optional lipid.
NºPublicación: US2017079962A1 23/03/2017
RAPAMYCIN HOLDINGS LLC [US]
The disclosure teaches counter-intuitive methods for treating stomatitis using oral mTOR inhibiting preparations such as preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The methods, preparations and other teachings are useful in various respects, especially for assisting in the treatment, prevention and management of stomatitis in feline subjects and, most especially, the treatment and management of Feline Chronic Gingivo-Stomatitis (FOGS), with secondary applications also related to management of gingivitis and autoimmune mucosal disorders. Disclosed embodiments illustrate multi-week dosing regimens and also address needs for alternative preparations or manufacturing processes that ensure efficacy while improving other performance characteristics such as storage stability, biodistribution, dosage cost, etc.
Nº publicación: US2017080058A1 23/03/2017
NANOPHARMACEUTICALS LLC [US]
Resumen de: US2017080058A1
Thyroid hormone antagonists and their nanoparticle formulations (Nanotetrac™ or Nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that are targets in the development of inflammation-suppressant drugs. This application discloses a novel composition of Tetra or Tri-iodothyroacetic acid (tetrac or triac), other thyroid partial agonists or antagonists and their nanoparticle formulations conjugated to polymers and encapsulating non-steroidal anti-inflammatory, anti-inflammatory glucocorticoids, and/or polyphenols for the management of various acute and chronic inflammatory disorders ranging from neurological, vascular, and musculoskeletal disorders.